Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of TQH2929 in Healthy Adult Subjects
Latest Information Update: 28 Mar 2025
At a glance
- Drugs TQH 2929 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 25 Mar 2025 Status changed from recruiting to completed.
- 12 Dec 2023 New trial record